William E. Martin

Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS

Since July 27, 2023

Age

49 years

Education

Holds a Bachelor of Science in Biochemistry from the University of Iowa.

Tenure

Joined MRVI in September 2022, initially serving as CEO before being placed on paid leave due to a legal dispute, then appointed as President of the Biologics Safety Testing operating division on December 05, 2022, and finally assumed the current CEO role on July 27, 2023.

Also at MARAVAI LIFESCIENCES HOLDINGS

Christine Dolan

Executive Vice President and General Manager, Cygnus Technologies

Kevin Herde

Chief Financial Officer (CFO)

Kurt Oreshack

Executive Vice President, General Counsel, and Secretary

About

William E. Martin, currently aged 49 as of March 25, 2024 , holds a Bachelor of Science in Biochemistry from the University of Iowa. His academic background provided the foundation for a long career in life sciences, beginning in March 1994 at Integrated DNA Technologies where he held various leadership roles over more than two decades.

In his professional journey, he served as Chief Operating Officer at IDT and later took on senior roles at Danaher Corporation, including President of the IDT business and Senior Vice President of New Business – Genomic Medicine. These roles underscored his capability in steering business growth and innovation in genomic medicine.

At MRVI, he first joined in September 2022, and despite an initial challenge that led to a brief tenure as CEO followed by a paid leave due to legal issues, his expertise led to his appointment as President of the Biologics Safety Testing operating division on December 05, 2022. Ultimately, his tenure was solidified with his appointment as the current CEO on July 27, 2023. His leadership is marked by a commitment to driving scientific breakthroughs and operational excellence at MRVI.

$MRVI Performance Under William E. Martin

Past Roles

Organization	Role	Date Range	Details
Maravai LifeSciences Holdings, Inc.	President, Biologics Safety Testing operating division	Dec 5, 2022 - Jul 27, 2023	Appointed after settlement of lawsuit regarding noncompetition agreement
Maravai LifeSciences Holdings, Inc.	Chief Executive Officer (interim)	Sep 30, 2022 - Oct 18, 2022	Placed on paid leave of absence due to lawsuit
Danaher Corporation	Senior Vice President, New Business – Genomic Medicine	Jul 2021 - Jul 2022	Joined after acquisition of IDT
Danaher Corporation	President of the IDT business	Apr 2018 - Jul 2021	Served as President under Danaher’s ownership following IDT acquisition
Integrated DNA Technologies	Chief Operating Officer	Mar 1994 - Apr 2018	Held various roles since 1994 and was COO at the time of acquisition
Other Employers	Not Disclosed	N/A	Involved in a lawsuit alleging violation of a noncompetition agreement; names undisclosed

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$750,000	Annual	Fixed annual cash compensation
Perquisites and Other Personal Benefits	$228,714	Annual	Cost for private aircraft use as per the aircraft bridge lease agreement
Company Contributions to 401(k) Plan	$9,150	Annual	Matching contributions to 401(k) plan

Performance Compensation

Data from FY 2023

Annual Bonus Opportunity

Metric	Weight	Threshold	Target	Maximum
Revenue	50%	$368.64M	$460.8M	$552.96M
Adjusted EPS	50%	$0.252	$0.42	$0.588

Evaluation Period: Annual performance measurement for 2023. Linear interpolation applies between threshold, target, and maximum. If the threshold is not met for either metric, no bonus is payable for that portion.

Equity Awards (Performance Stock Units – August 21, 2023)

Detail	Value	Additional Details
Grant Date	Aug 21, 2023	Date on which the PSUs were granted
Grant Date Fair Value	$1,314,000	Fair value of the PSUs awarded in 2023
Grant Date Stock Price	$10.48	Closing price on the grant date
Vesting Condition (Tier 1)	50,000 PSUs	Vest when 60-day volume-weighted average price is at least $15 (43% increase from grant date)
Vesting Condition (Tier 2)	125,000 PSUs	Vest when price reaches $25 (139% increase from grant date)
Vesting Condition (Tier 3)	125,000 PSUs	Vest when price reaches $30 (186% increase from grant date)
Employment Condition	Continued employment	Must remain employed through Aug 21, 2026
Change in Control	Conversion to time-based RSUs	In the event of a Change in Control, PSUs convert to RSUs that vest on Aug 21, 2026

Additional Details: The PSUs are linked to the 60-day volume-weighted average stock price. The performance targets and vesting conditions are designed to align Mr. Martin's compensation with long-term shareholder value creation.